FDA aims to pull Shire's blood pressure drug from the market

08/16/2010 | Wall Street Journal, The

The FDA is seeking to withdraw Shire's ProAmatine from the market because the drugmaker failed to conduct follow-up trials to demonstrate the drug's clinical benefit in patients with orthostatic hypotension. The treatment, generically known as midodrine hydrochloride, received accelerated approval in 1996.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI